Monteris Medical will present its NeuroBlate system for magnetic resonance (MR)-guided neurosurgical ablation of brain lesions at the Bienniel meeting of the American Society of Stereotactic and Functional Neurosurgery on 3 June in Washington, D.C.
Cleveland Clinic Rose Ella Burkhardt Brain Tumor and NeuroOncology Center director Dr Gene Barnett will present his experience utilizing NeuroBlate system laser ablation in patients with brain tumors and radiation necrosis.
Dr Barnett has shown that by employing magnetic resonance imaging and software based visualization offered by the NeuroBlate system he is often able to completely ablate (treat with high heat) tumors through a very small hole in the skull.
Monteris Medical president and CEO John E Schellhorn said that the company is pleased to have the NeuroBlate system included in this scientific meeting agenda.
"Patients who have received this minimally invasive laser ablation therapy for brain lesions have gone to post-surgical recovery with a small bandage on their scalp rather than a large suture line. We are proud of our technology’s contribution to less-invasive brain surgery," Schellhorn added.
Monteris Medical’s NeuroBlate system has already received approval from the US Food and Drug Administration. The novel brain ablation device has been approved to ablate, necrotize or coagulate soft tissue encountered in the discipline of neurosurgery through the application of thermal therapy.
Physicians can address various medical conditions including brain tumors and tissue inflamed by radiation necrosis, among others, with the help of the NeuroBlate system.
NeuroBlate is not indicated to treat, cure, prevent, mitigate or diagnose any specific disease, including radiation necrosis.